Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

20.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 20.32
Bid (Size) 20.21 (2)
Ask (Size) 20.50 (1)
Prev. Close 20.32
Today's Range 20.32 - 20.32
52wk Range 11.55 - 20.87
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily

Performance

YTD
+18.76%
+18.76%
1 Month
+15.52%
+15.52%
3 Month
+22.63%
+22.63%
6 Month
+43.30%
+43.30%
1 Year
+43.00%
+43.00%

More News

Read More
Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents.
Via Chartmill
NASDAQ:CPRX stands out as a growth opportunity that won't break the bank.
Via Chartmill
Immunome Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Via Benzinga
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
Via Investor's Business Daily
Top 3 Health Care Stocks That May Crash In August
Via Benzinga
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
Via Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.